phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"phgenomics-176Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDYСопоставление активности изофермента цитохрома Р450 CYP2C9 у пациентов пожилого и старческого возраста и у здоровых добровольцев первого периода зрелого возрастаComparative analysis of cytochrome P450 isoform CYP2C9 in elderly and senile patients with that in healthy volunteers of the first period of middle ageСычёвД. А.SychevD. A.

г. Москва

Moscow

БордовскийС. П.BordovskyS. P.

Бордовский Сергей Петрович – студент 5 курса.

тел. +7 (967) 269-16-47

Moscow

Arhont7@bk.ruНикулинВ. Э.NikulinV. E.

г. Москва

Moscow

ПольшинаН. И.PolshinaN. I.

г. Москва

Moscow

АникинГ. С.AnikinG. S.

г. Москва

Moscow

ДанилинаК. С.DanilinaK. S.

г. Москва

Moscow

СмирновВ. В.SmirnovV. V.

г. Москва

Moscow

ОтделеновВ. А.OtdelenovV. A.

г. Москва

Moscow

ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Министерства здравоохранения Российской ФедерацииРоссияFSBEI FPE Russian Medical Academy of Continuous Professional Education of Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО Первый МГМУ им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian FederationФГБОУ ВО Первый МГМУ им. И.М. Сеченова; Институт иммунологии ФМБА РоссииРоссияFirst Moscow State Medical University named after I.M. Sechenov; NRC Institute of Immunology FMBA of RussiaRussian Federation201625032020021923Copyright © Сычёв Д.А., Бордовский С.П., Никулин В.Э., Польшина Н.И., Аникин Г.С., Данилина К.С., Смирнов В.В., Отделенов В.А., 20202020Сычёв Д.А., Бордовский С.П., Никулин В.Э., Польшина Н.И., Аникин Г.С., Данилина К.С., Смирнов В.В., Отделенов В.А.Sychev D.A., Bordovsky S.P., Nikulin V.E., Polshina N.I., Anikin G.S., Danilina K.S., Smirnov V.V., Otdelenov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/176лекарственная терапияCYP2C9лозартанпожилые пациентыпациенты старческого возрастаdrug therapyCYP2C9 isoformlosartanelderly peoplesenile peopleReferencesOsadchih A.I., Puzin S.N., Lavrova D.I. et al. Problems of disability in Russia. State and prospects; Medicine, 2002: 368.Osadchih A.I., Puzin S.N., Lavrova D.I. et al. Problems of disability in Russia. State and prospects; Medicine, 2002: 368.Denisova T.P., Malinova L.I. Clinical Gerontology: Selected Lectures. Moscow: LLC ‘Medical information agency’, 2008: 256.Denisova T.P., Malinova L.I. Clinical Gerontology: Selected Lectures. Moscow: LLC ‘Medical information agency’, 2008: 256.Page K., Curtis M., Woker B., Hoffman B. Pharmacology: a clinical approach. Moscow: Logospheraю 2012: 744.Page K., Curtis M., Woker B., Hoffman B. Pharmacology: a clinical approach. Moscow: Logospheraю 2012: 744.Belousov U.B., Leonova M.V. Special aspects of drug therapy in geriartric practice. Pharmatekaю 2008; 8; 13–19.Belousov U.B., Leonova M.V. Special aspects of drug therapy in geriartric practice. Pharmatekaю 2008; 8; 13–19.Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002; 72; 702–710.Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002; 72; 702–710.Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokine.t 2007; 46; 271–279.Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokine.t 2007; 46; 271–279.Shi S., Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64; 233–252.Shi S., Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64; 233–252.Jetter A., Kinzig-Schippers M., Skott A. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmaco.l 2004; 60: 3; 165–171.Jetter A., Kinzig-Schippers M., Skott A. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmaco.l 2004; 60: 3; 165–171.George M., Shewade D.G., Kumar S.V., Adithan C. Effect of antituberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug. Indian J Pharmacol. 2012; 44; 4: 485–488.George M., Shewade D.G., Kumar S.V., Adithan C. Effect of antituberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug. Indian J Pharmacol. 2012; 44; 4: 485–488.Sychev D.A. Russian guidelines for studying biotransformation and new drug transporter testing by pharmaceutical companies: study desings, data analysis, data entry in products’ instructions. Available at: URL: http://www.regmed.ru/Content/Doc.aspx?id=26a9128c-ee32-4469-9c64-5c666339049eSychev D.A. Russian guidelines for studying biotransformation and new drug transporter testing by pharmaceutical companies: study desings, data analysis, data entry in products’ instructions. Available at: URL: http://www.regmed.ru/Content/Doc.aspx?id=26a9128c-ee32-4469-9c64-5c666339049eJoy M.S., Dornbrook-Lavender K., Blaisdell J., Hilliard T., Boyette T., Hu Y., Hogan S.L., Candiani C., Falk R.J., Goldstein J.A. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Clin Pharmacol. 2009; 65: 9: 947–953.Joy M.S., Dornbrook-Lavender K., Blaisdell J., Hilliard T., Boyette T., Hu Y., Hogan S.L., Candiani C., Falk R.J., Goldstein J.A. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Clin Pharmacol. 2009; 65: 9: 947–953.Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. Journal of Clin Pharmacy and Therapeutics. 1998; 23; 247–255.Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. Journal of Clin Pharmacy and Therapeutics. 1998; 23; 247–255.

The authors declare that there are no conflicts of interest present.